Altering Metabolic Pathways To Override Drug Resistance in Cancer
ISEF · 2022 Biomedical and Health Sciences
Overview
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly lethal and aggressive form of pancreatic cancer with a 5-year survival rate of 8%. This form of cancer is particularly hard to treat due to late diagnosis, the rapid development of drug resistance, and the dense microenvironment surrounding the cancer cells. Increasing evidence has shown that the reprogrammed metabolism of pancreatic cancer may play a role in tumor progression, prognosis, and treatment. Two transmembrane proteins that play an important role in cancer metabolism are syndecan-1 and glut-1. Glut-1 is a transmembrane protein that facilitates cellular glucose uptake, providing glucose for glycolysis and other complex metabolic pathways. Syndecan-1 is a transmembrane proteoglycan that has high levels of expression in cancer cells. This protein is a critical mediator of macropinocytosis. Macropinocytosis (“cell-scavenging”) is the uptake of nutrients from the extracellular matrix through the cell membrane. Both syndecan-1 and glut-1 are promising candidates that could affect the metabolic pathways of pancreatic cancer and potentially decrease cell viability if inhibited. Due to pancreatic cancer’s ability to resist treatment, combination therapies hold the greatest promise in therapeutic effect. Previous studies have forged a link between the starvation of cancer cells and increased chemosensitivity. Therefore, if both syndecan-1 and glut-1 are selectively inhibited and then treated with a chemotherapeutic agent, PDAC cells will demonstrate decreased proliferation and decrease ability to develop drug resistance. This study will investigate if inhibition of both syndecan-1 and glut-1could starve pancreatic cancer cells and promote chemosensitivity.
Competition history
- ISEF 2022
Resources
Related projects
ISEF · 2018
Targeting a Redox Dependency in Pancreatic Ductal Adenocarcinoma
ISEF · 2024
The Effect of UPP1, A Novel Metabolic Suppressor vs. Oncolytic Viruses on Pancreatic Cancers
ISEF · 2025
Investigating the Role of Nicotinamide Adenine Dinucleotide Precursors in Pancreatic Cancer Prevention
ISEF · 2025
Decoding PDAC: A scRNA-seq Omics Analysis to Unveil and Inhibit Key Protein Using a Novel in-silico, Structure-Based Drug Design Pipeline
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair